Dizal to present clinical data on cancer therapies at ASH 2026
Pharmaceutical company Dizal will share findings on golidocitinib and birelentinib in treating hematologic malignancies at the upcoming ASH conference.
Dizal Pharmaceutical has confirmed plans to present clinical trial results at the American Society of Hematology (ASH) 2026 meeting. The updates will cover the development of golidocitinib and birelentinib, two key assets in the company’s pipeline.
The presentations will include findings for golidocitinib as a monotherapy for adults diagnosed with secondary hemophagocytic lymphohistiocytosis (HLH). The company reports observed response rates, which will be detailed during an oral session at the event.
Additionally, Dizal will provide clinical data regarding the use of birelentinib for first-line treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Two oral presentations will focus on its efficacy when administered as a standalone therapy and in combination with a BCL2 inhibitor.
These results serve as a progress update for the firm's oncology program as it seeks to demonstrate the therapeutic potential of these agents in competitive hematology markets.